Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 5/2012

01.10.2012 | Voiding Dysfunction and Lower Urinary Tract Symptoms (GH Badlani and HB Goldman, Section Editors)

Bladder Augmentation and Urinary Diversion for Neurogenic LUTS: Current Indications

verfasst von: Kamran P. Sajadi, Howard B Goldman

Erschienen in: Current Urology Reports | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Augmentation cystoplasty and urinary diversion are no longer commonplace in the management of patients with neurogenic bladder, but remain an important surgical treatment for those with refractory LUTS who have failed neuromodulation and onabotulinum toxin treatment or who are not candidates for those treatments. Augmentation is an option in patients who can perform intermittent catheterization and is usually performed with ileum or large intestine. Some patients benefit from continent cutaneous catherizable channels. Supravesical urinary diversion may be necessary in more severe cases. Ileovesicostomies are being supplanted by indwelling suprapubic catheters, and when catheters fail conduits may be a better option. When feasible, the diverted bladder should be excised to avoid pyocystis.
Literatur
1.
• Biers SB, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJUI. 2011;109:1280–93. An excellent review of the current role for augmentation cystoplasty.CrossRef
2.
• Padmanabhan P, Scarpero HM, Milam DF, Dmochowski RR, Penson DF. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol. 2011;29:51–7. This cost analysis compares onabotulinum toxin with augmentation cystoplasty, considering variables of efficacy duration and complication rates. PubMedCrossRef
3.
Watanabe JH, Campbell JD, Ravelo A, et al. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010;76:835–40.PubMedCrossRef
4.
5.
Khoury JM, Webster GD. Augmentation cystoplasty. World J Urol. 1990;8:203–4.CrossRef
6.
• Ivancić V, DeFoor W, Jackson E, et al. Progression of renal insufficiency in children and adolescents with neuropathic bladder is not accelerated by lower urinary tract reconstruction. J Urol. 2010;184:1768–74. A series of pediatric patients undergoing augmentation mostly had stable or improved renal function, whereas conventional wisdom would suggest they should undergo incontinent diversion. PubMedCrossRef
7.
Cartwright PC, Snow BW. Bladder autoaugmentation: early clinical experience. J Urol. 1989;142:505–8.PubMed
8.
Rivas DA, Chancellor MB, Huang B, Epple A, Figueroa TE. Comparison of bladder rupture pressure after intestinal bladder augmentation (ileocystoplasty) and myomyotomy (autoaugmentation). Urology. 1996;48:40–6.PubMedCrossRef
9.
Perovic SV, Djordjevic ML, Kekic ZK, Vukadinovic VM. Detrusorectomy with rectus muscle hitch and backing. J Pediatr Surg. 2003;38:1637–41.PubMedCrossRef
10.
Gurocak S, De Grier RP, Feitz W. Bladder augmentation without integration of intact bowel segments: critical review and future perspectives. J Urol. 2007;177:839–44.PubMedCrossRef
11.
Rocha FT, Bruschini H, Figueiredo JA, et al. Use of an inflatable silicone balloon improves the success rate of bladder autoaugmentation at long-term followup. J Urol. 2011;185:2576–81.PubMedCrossRef
12.
Kaibafzadeh AM, Farrokhi-Khajeh-Pasha Y, Ostovaneh MR, Nezami BG, Hojjat A. Teapot ureterocystoplasty and ureteral Mitrofanoff channel for bilateral megaureters: technical points and surgical results of neurogenic bladders. J Urol. 2010;183:1168–74.CrossRef
13.
Johal NS, Hamid R, Aslam Z, et al. Ureterocystoplasty: long-term functional results. J Urol. 2008;179:2373–5.PubMedCrossRef
14.
Barrett D. Surgery for the neuropathic patient (Committee 20). In: Abrams P, Khoury S, Wein A, editors. Incontinence. London: Health Publication Limited; 1999. p. 813–6.
15.
• Gurung, Attar KH, Abdul-Rahman A, et al. Long-term outcomes of augmentation ileocystoplasty in patients with spinal cord injury: a minimum of 10 years of follow-up. BJU Int. 2012;109:1236–42. One of the largest and longest series of neurologically impaired patients who have undergone ileocystoplasty, demonstrating the long-term success and satisfaction. PubMedCrossRef
16.
Vaida P, Pinter AB, Harangi F, et al. Metabolic findings after colocystoplasty in children. Urology. 2003;62:542–6.CrossRef
17.
Sarosdy MF. Continent urinary diversion using cutaneous ileocecocystoplasty. Urology. 1992;40:102–6.PubMedCrossRef
18.
• Choi J, Liu J, Boone T, Fletcher S. Ileocecal augmentation cystoplasty: “The Indiana Augment.”. Neurourol Urodyn. 2011;30:1070–70. The largest available series demonstrating the success of ileocecocystoplasty as a combination augmentation and continent catheterizable channel.
19.
Shakeri S, Aminsharifi A, Jahanabadi Z. Application of appendicular-based cecal flap for less invasive augmentation cystoplasty: a novel technique. Urol Int. 2009;83:271–6. The authors present a novel technique for augmentation and catheterizable channel that uses a portion of cecum without requiring bowel anastomosis.PubMedCrossRef
20.
Adams MC, Mitchell ME, Rink RC. Gastrocystoplasty: an alternative solution to the problem of urological reconstruction in the severely compromised patient. J Urol. 1988;140:1152–6.PubMed
21.
Leonard MP, Dharamsi N, Williot PE. Outcome of gastrocystoplasty in tertiary pediatric urology practice. J Urol. 2000;164:947–50.PubMedCrossRef
22.
• Leslie B, Lorenzo AJ, Moore K, et al. Long-term follow-up and time to event outcome analysis of continent catheterizable channels. J Urol. 2011;185:2298–302. This large and long series of pediatric patients with continent catheterizable channels illustrates the channel-related complication and reoperation rates. PubMedCrossRef
23.
Van der Aa F, Joniau S, De Baets K, De Ridder D. Continent catheterizable vesicostomy in an adult population: success at high costs. Neurourol Urodyn. 2009;28:487–91.PubMedCrossRef
24.
Eisenberg L, Johnson J, Santucci R. Pilot study of the vesicocutaneous continent catheterizable stoma (Mitrofanoff) in adults – high complication rates. Urology. 2012;79:222–6.PubMedCrossRef
25.
Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol. 2005;173:1318–22.PubMedCrossRef
26.
• Hellenthal NJ, Short SS, O’Connor RC, et al. Incontinent ileovesicostomy: long-term outcomes and complications. Neurourol Urodyn. 2009;28:483–6. An excellent series of patients undergoing ileovesicostomy shows a high rate of complications and reoperations, including conversion to ileal conduit. PubMedCrossRef
27.
Fazili T, Bhat TR, Masood S, Palmer JH, Mufti GR. Fate of the leftover bladder after supravesical urinary diversion for benign disease. J Urol. 2006;176:620–1.PubMedCrossRef
28.
Eigner EB, Freiha FS. The fate of the remaining bladder following supravesical diversion. J Urol. 1990;144:31–3.PubMed
29.
Tung GA, Papanicolaou N. Pyocystis with urethral obstruction: percutaneous cystostomy as an alternative to surgery. Can Assoc Radiol J. 1990;41:350–2.PubMed
30.
Singh G, Wilkinson JM, Thomas DG. Supravesical diversion for incontinence: a long-term follow-up. Br J Urol. 1997;79:348–53.PubMedCrossRef
31.
Doherty AP, Bellringer J. Stapled vaginal vesicostomy for pyocystis in the defunctioned female bladder. BJU Int. 1999;83:339–40.PubMedCrossRef
32.
Lees JA, Falk RM, Stone WJ, McDougal WS. Pyocystis, pyonephrosis and perinephric abscess in end stage renal disease. J Urol. 1985;134:716–9.PubMed
33.
Granados EA, Salvador J, Vicente J, Villavicencio H. Follow-up of the remaining bladder after supravesical urinary diversion. Eur Urol. 1996;29:308–11.PubMed
Metadaten
Titel
Bladder Augmentation and Urinary Diversion for Neurogenic LUTS: Current Indications
verfasst von
Kamran P. Sajadi
Howard B Goldman
Publikationsdatum
01.10.2012
Verlag
Current Science Inc.
Erschienen in
Current Urology Reports / Ausgabe 5/2012
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-012-0271-z

Weitere Artikel der Ausgabe 5/2012

Current Urology Reports 5/2012 Zur Ausgabe

Voiding Dysfunction and Lower Urinary Tract Symptoms (GH Badlani and HB Goldman, Section Editors)

How Do Urodynamics Findings Influence the Treatment of the Typical Patient With Overactive Bladder?

Voiding Dysfunction and Lower Urinary Tract Symptoms (GH Badlani and HB Goldman, Section Editors)

Evaluation and Management of Outlet Obstruction in Women Without Anatomical Abnormalities on Physical Exam or Cystoscopy

Voiding Dysfunction and Lower Urinary Tract Symptoms (GH Badlani and HB Goldman, Section Editors)

The Incidence and Etiology of Overactive Bladder in Patients After Cerebrovascular Accident

Voiding Dysfunction and Lower Urinary Tract Symptoms (GH Badlani and HB Goldman, Section Editors)

The Treatment of Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis: A Systematic Review

Voiding Dysfunction and Lower Urinary Tract Symptoms (GH Badlani and HB Goldman, Section Editors)

Practical Use of the New American Urological Association Interstitial Cystitis Guidelines

Voiding Dysfunction and Lower Urinary Tract Symptoms (GH Badlani and HB Goldman, Section Editors)

Percutaneous Tibial Nerve Stimulation: A Clinically and Cost Effective Addition to the Overactive Bladder Algorithm of Care

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise